Abstract |
Immune checkpoint inhibitors, widely used in the treatment of malignancies, can improve the prognosis of patients, while it also can induce various immune-related adverse events, and type 1 diabetes induced by anti-programmed cell death protein-1 is a rare but severe complication. Here we reported a case of type 1 diabetes induced by anti-PD-1 which was to treat intrahepatic cholangiocarcinoma. The case was a 61-year-old female who developed diabetes and ketoacidosis symptoms at the 16th week after anti-PD-1 therapy. Her blood glucose was 30.32 mmol/L, HBA1c was 8.10%, and C-peptide was <0.10 ng/ml. The patient was diagnosed as fulminant type 1 diabetes mellitus complicated with ketoacidosis induced by anti-PD-1, and was treated with massive fluid rehydration, intravenous infusion of insulin and correction of acid-base electrolyte disorder. Hepatectomy was performed after stabilization, and the patient was treated with long-term insulin. Through the case report and literature review, this study aims to improve oncologists' understanding of anti-PD-1 induced type 1 diabetes, so as to make early diagnosis and treatment of the complications and ensure medical safety.
|
Authors | Zhi-Kai Zheng, Jiong-Liang Wang, Wen-Xuan Li, Tian-Qing Wu, Min-Shan Chen, Zhong-Guo Zhou |
Journal | Frontiers in public health
(Front Public Health)
Vol. 10
Pg. 917679
( 2022)
ISSN: 2296-2565 [Electronic] Switzerland |
PMID | 35784237
(Publication Type: Case Reports, Review, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2022 Zheng, Wang, Li, Wu, Chen and Zhou. |
Chemical References |
|
Topics |
- Bile Duct Neoplasms
(complications, drug therapy)
- Bile Ducts, Intrahepatic
- Cell Death
- Cholangiocarcinoma
(complications, drug therapy)
- Diabetes Mellitus, Type 1
(complications, diagnosis)
- Female
- Humans
- Insulins
(adverse effects)
- Ketosis
(complications)
- Middle Aged
|